Silicon Republic July 25, 2022
This UCD biotech spin-out is combining algorithms and the study of proteins to better detect disease biomarkers in blood samples.
“Our vision is to help patients and doctors with their decision-making,” said Robert Perryman, CEO of Atturos.
“From its start, Atturos has been listening to and working closely with patient representative groups, clinicians and industry to identify the unmet needs where our technology and products will make a significant difference to patient care.”
A spin-out of University College Dublin (UCD), Atturos combines data science and machine learning analytics with proteomics, the large-scale study of proteins, to deliver what Perryman calls “highly specific, personalised diagnostic information”.
Personalised medicine is poised to revolutionise healthcare, giving clinicians the ability to prescribe treatment tailored...
Today's Sponsors
Today's Sponsor